<DOC>
	<DOCNO>NCT02187445</DOCNO>
	<brief_summary>Acute chronic pulmonary complication concomitant inflammatory response lead cause morbidity mortality child sickle cell disease ( SCD ) . Acute chest syndrome ( ACS ) , define broadly increase respiratory effort , fever new radiodensity chest x-ray , major cause death child adult SCD . There high rate ACS child 1 4 year age associate asthma diagnosis , child ACS event 4 year age 50 % rate hospitalize either ACS pain within 1 year admission . For child SCD develop ACS , investigator propose use budesonide inhalation suspension ( BIS ) attenuate pulmonary inflammation ACS episode decrease future vaso-occlusive pain ACS episode . Through single-arm prospective feasibility trial preparation limited-institution randomize trial , investigator plan test follow primary hypothesis phase III definitive trial : In child SCD admit hospital ACS episode 1 4 year age , low dose BIS 6 month result 50 % reduction recurrent incidence rate ACS pain require hospitalization . Through trial , investigator determine acceptability adherence BIS study population . The investigator track respiratory symptom case versus control 6 month . Finally , investigator explore impact BIS biological correlate ( sVCAM-1 ) .</brief_summary>
	<brief_title>Inhaled Corticosteroid Use Prevent Acute Chest Syndrome Recurrence Children Between 1 4 With Sickle Cell Disease : Feasibility Trial</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Acute Chest Syndrome</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1 ) confirm diagnosis sickle cell disease ( SCD ) 2 ) age 1 4 year ( must reach 1st yet 4th birthday ) 3 ) prior diagnosis ACS , define acute respiratory illness new radiodensity CXR , one following : fever ( temperature &gt; 38.50C ) , decrease oxygen saturation 3 % baseline , increase respiratory rate baseline 1 ) patient already take inhaled corticosteroid 2 ) receive blood transfusion elevate TCD stroke 3 ) present 2 week discharge hospital follow initial ACS episode . Participants may hydroxyurea participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>4 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Budesonide inhalation suspension</keyword>
	<keyword>Acute Chest Syndrome</keyword>
</DOC>